Abbott Laboratories (NY:ABT)

97.50 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

58 59 Next >

Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday ↗

March 27, 2025

Via The Motley Fool

Which S&P500 stocks are moving on Thursday? ↗

March 27, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

March 27, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets ↗

March 27, 2025

Via Benzinga

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment ↗

March 10, 2025

Via Benzinga

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment ↗

March 06, 2025

Via Benzinga

2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income ↗

March 26, 2025

Via The Motley Fool

No Quick Fix For This Market ↗

March 23, 2025

Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.

Via Talk Markets

Topics Stocks / Equities

What Does the Market Think About Abbott Laboratories? ↗

March 20, 2025

Via Benzinga

Where Abbott Laboratories Stands With Analysts ↗

March 04, 2025

Via Benzinga

What Does the Market Think About Abbott Laboratories? ↗

February 28, 2025

Via Benzinga

Looking Into Abbott Laboratories's Recent Short Interest ↗

February 11, 2025

Via Benzinga

Decoding Abbott Laboratories's Options Activity: What's the Big Picture? ↗

March 18, 2025

Via Benzinga

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

March 14, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends.

Via Chartmill

Q4 Earnings Roundup: CooperCompanies (NASDAQ:COO) And The Rest Of The Medical Devices & Supplies - Diversified Segment

March 13, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including CooperCompanies (NASDAQ:COO) and its peers.

Via StockStory

3 Reasons to Avoid ABT and 1 Stock to Buy Instead

March 10, 2025

Abbott Laboratories’s 16.6% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $136.50 per share. This run-up might have investors contemplating their...

Via StockStory

Topics Stocks

Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock ↗

March 07, 2025

Via Benzinga

Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock ↗

March 07, 2025

Via Benzinga

2 Dependable Dividend Stocks That Can Pay You for Life ↗

March 07, 2025

Via The Motley Fool

Indications Suggest ABBOTT LABORATORIES (NYSE:ABT) Could Be on the Verge of a Breakout. ↗

February 28, 2025

Exploring ABBOTT LABORATORIES's Technical Signals and Breakout Potential: ABBOTT LABORATORIES is showing promising signs of setting up for a breakout.

Via Chartmill

3 Reasons ABBV is Risky and 1 Stock to Buy Instead

February 28, 2025

AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.

Via StockStory

Topics Stocks

Medical Devices & Supplies - Diversified Stocks Q4 Teardown: Stryker (NYSE:SYK) Vs The Rest

February 28, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified...

Via StockStory

Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & Supplies - Diversified Segment

February 25, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4,...

Via StockStory

Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market ↗

February 24, 2025

Many analysts are feeling better about the prospects for healthcare stocks in 2025.

Via Talk Markets

Topics ETFs Stocks / Equities

Q4 Earnings Highs And Lows: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

February 24, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers.

Via StockStory

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom ↗

February 14, 2025

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential.

Via Benzinga

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗

February 13, 2025

Via The Motley Fool

Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know ↗

February 12, 2025

Via Benzinga

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now ↗

February 10, 2025

Via The Motley Fool

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.